Welcome to our dedicated page for LNDC news (Ticker: LNDC), a resource for investors and traders seeking the latest updates and insights on LNDC stock.
Landec Corporation (Nasdaq: LNDC) is a pioneering force in the realm of diversified health and wellness solutions, operating primarily through its two main subsidiaries: Curation Foods, Inc. and Lifecore Biomedical, Inc.
Curation Foods focuses on delivering plant-based foods made from 100% clean ingredients. Their product lines include the Eat Smart® brand of fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products, and Yucatan® and Cabo Fresh® avocado products. Curation Foods ensures the utmost freshness of its offerings through a robust family of geographically dispersed growers, a refrigerated supply chain, and its patented BreatheWay® packaging technology. These products are distributed across retail, club, and foodservice channels throughout North America.
Lifecore Biomedical, on the other hand, is a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products in syringes and vials. Lifecore is renowned for its production of premium, injectable-grade Hyaluronic Acid and has over 35 years of experience serving global and emerging biopharmaceutical and biotechnology companies. The company's capabilities span multiple therapeutic categories, making it a trusted partner in bringing innovative drugs to market.
Recently, Lifecore Biomedical has entered into a non-exclusive co-marketing partnership agreement with SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors. This partnership aims to leverage SHL's expertise in drug delivery device solutions and Lifecore's proficiency in aseptic pharmaceutical manufacturing to offer a comprehensive support system for the development and commercialization of autoinjector products.
This collaboration will enable both companies to provide their customers with unparalleled guidance in CDMO services and innovative options for drug delivery device development. The partnership is expected to enhance Lifecore's service offerings, enabling customers to deliver the benefits and convenience of cutting-edge drug delivery systems to patients worldwide.
Landec Corporation continues to adapt and evolve with industry trends, maintaining a strong financial position and strategic partnerships that bolster its market presence and operational capabilities.
Landec Corporation (Nasdaq: LNDC) will announce its fiscal first quarter 2022 results on September 29, 2021, after market close. The conference call will take place at 2 p.m. Pacific time, featuring CEO Dr. Albert Bolles, CFO John Morberg, and Lifecore President Jim Hall. The presentation will include a Q&A session. A replay will be available for one week until October 6, 2021. Landec operates two businesses: Lifecore Biomedical, a CDMO for sterile injectables, and Curation Foods, focusing on innovative plant-based products. More details are available on Landec’s website.
Landec Corporation (LNDC) reported fiscal 2021 results, showing a 14.3% revenue growth and 23.1% net income growth, while adjusted EBITDA rose 22.0%. Total revenues reached $544.2 million but net loss was $32.7 million. Lifecore Biomedical's revenue grew 14% with adjusted EBITDA of $24.5 million, whereas Curation Foods faced a 12% revenue decline. The company expects fiscal 2022 revenues between $545 million and $554 million, reflecting flat growth. CEO Dr. Albert Bolles emphasized ongoing efforts to drive shareholder value via strategic investments and operational improvements.
Landec Corporation (Nasdaq: LNDC) will hold a conference call on July 28, 2021, at 2 p.m. Pacific Time to discuss its fiscal fourth quarter 2021 results. The results, covering the period ending May 31, 2021, will be announced after market close on the same day. The call will feature CEO Dr. Albert Bolles, CFO John Morberg, and Lifecore President Jim Hall, followed by a Q&A session. Interested parties can access the call via telephone or webcast, with a replay available for a week after the event.
Landec Corporation (LNDC) announced the sale of its equity interests in Windset Holdings for $45.1 million to affiliates of Windset's founding investors. The sale, equaling the carrying value, enables Landec to repay $41.2 million in term debt, reducing its net debt leverage from 5.8x to 4.6x. This strategic move is part of Landec’s Project SWIFT framework aimed at enhancing shareholder value. The company anticipates a reduction in annual interest expense by approximately $3.9 million following the debt repayment, though it expects to incur fees of $3.9 million related to this transaction.
Lifecore Biomedical, a subsidiary of Landec Corporation (LNDC), has announced the FDA approval of ZYNRELEF on May 13, 2021. This extended-release local anesthetic, combining bupivacaine and meloxicam, is designed for postoperative pain management following surgeries like bunionectomy and total knee arthroplasty. ZYNRELEF offers longer analgesia (up to 72 hours) and has shown to reduce opioid use post-surgery. Lifecore's role in developing the manufacturing process showcases its capabilities in meeting stringent pharmaceutical standards.
Landec Corporation (Nasdaq: LNDC) has entered into a strategic logistics partnership with Castellini Company to enhance Curation Foods' operations. This partnership aims to expand market reach, streamline logistics, and reduce costs. The agreement includes outsourcing logistics for fresh packaged salads and vegetables, leading to anticipated annual savings of $1.0 million starting fiscal 2022. However, Landec expects $3.0 million in restructuring costs in Q4 2021, mostly non-cash, due to facility closures and staff reductions. The company seeks to optimize its operations and improve profitability.
Lifecore Biomedical, a segment of Landec Corporation (Nasdaq: LNDC), reported significant year-to-date revenue growth of 20%, with net income increasing by 39% and adjusted EBITDA up 34% for the fiscal year-to-date period ended February 28, 2021. Total revenues reached $404.3 million, despite a 10% decrease in third-quarter revenues due to challenges in Curation Foods, whose revenues fell 13%. The company maintains its guidance for Lifecore while adjusting outlook for Curation Foods amid COVID-19 impacts.
Landec Corporation (Nasdaq: LNDC) is set to hold a conference call on April 7, 2021, at 2 p.m. Pacific time to discuss its financial results for the fiscal third quarter 2021, ending February 28, 2021. This teleconference follows the release of financial results after market close on the same day. CEO Dr. Albert Bolles will lead the discussion, joined by CFO John Morberg and Lifecore President Jim Hall. A Q&A session will follow the presentation, and interested parties can access the call via toll-free numbers or a webcast.
Landec Corporation (NASDAQ: LNDC) mourns the passing of board member Charles “Mac” Macaluso on February 22, 2021. He was a key advisor, whose expertise contributed significantly to Curation Foods' growth strategies and company refinancing. Macaluso served on the board since October 2019, participating in the Audit and Curation Focus Committees. His extensive cross-industry experience left a lasting impact, although his board seat will remain unfilled for now. The company emphasizes his legacy of excellence and the void his departure creates in leadership.
Landec Corporation (Nasdaq: LNDC) has appointed John D. Morberg as the new Chief Financial Officer, effective January 18, 2021, succeeding Brian McLaughlin, who has retired. Morberg brings over 25 years of experience in corporate finance and executive leadership, having previously served as CFO and General Counsel for a national restaurant chain. His appointment is seen as a strategic move to enhance Landec’s financial and operational capabilities as the company aims for growth and profitability.
FAQ
What is the market cap of LNDC (LNDC)?
What are the main subsidiaries of Landec Corporation?
What products does Curation Foods offer?
What is Lifecore Biomedical known for?
What recent partnership has Lifecore Biomedical entered into?
What does the BreatheWay® packaging technology do?
What are the distribution channels for Curation Foods' products?
How long has Lifecore Biomedical been in the industry?
What capabilities does Lifecore Biomedical offer?
What therapeutic categories does Lifecore Biomedical work in?